Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
geographic variation
migraine
opioid
prescribing patterns
triptan
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
22
09
2021
received:
18
02
2021
accepted:
30
09
2021
pubmed:
30
11
2021
medline:
10
2
2022
entrez:
29
11
2021
Statut:
ppublish
Résumé
To assess the geographic variations in triptan and opioid prescribing patterns for patients with migraine. Numerous guidelines recommend triptans as the standard of care for migraine attacks, yet opioids are still widely used for migraine treatment. Variation in the use of opioids and triptans for the treatment of migraine by geographic location is not well known. Using a US claims database, we conducted a retrospective cohort study of adults diagnosed with migraine between 2016 and 2018. We used a 12-month follow-up period to assess triptan and opioid utilization, stratified by the nine Census Bureau-designated divisions. To examine the geographic factors that affect triptan and opioid use among patients, we conducted two sets of multivariable analyses. First, we analyzed the odds of a patient being a triptan or opioid user in the follow-up period, defined as ≥1 triptan or opioid claim. We then analyzed the medication use rate among triptan or opioid users. Overall, we had a final study population of 113,921 patients. In the follow-up period, 52.9% (60,247/113,921) [range: 48.0%-56.3%] of patients were triptan users and 41.0% (46,708/113,921) [range: 28.9%-48.4%] of patients were opioid users with significant differences across census divisions (p < 0.001). Triptan users had a mean (SD) of 4.8 (4.7) triptan claims annually with no significant differences across divisions (p = 0.188). Opioid users had a mean (SD) of 5.4 (6.8) opioid claims annually with significant differences across divisions (p < 0.001). The observed variation in opioid use stemmed from the proportion of patients using opioids in each region and not from the number of opioid prescriptions per user. There was a significant geographic variation in the use of opioids and to a lesser degree the use of triptans. The widespread use of opioids and the large variation in use other than triptans as the standard of care suggest that improvements could be made in the acute treatment of migraine attacks.
Sections du résumé
OBJECTIVE
OBJECTIVE
To assess the geographic variations in triptan and opioid prescribing patterns for patients with migraine.
BACKGROUND
BACKGROUND
Numerous guidelines recommend triptans as the standard of care for migraine attacks, yet opioids are still widely used for migraine treatment. Variation in the use of opioids and triptans for the treatment of migraine by geographic location is not well known.
METHODS
METHODS
Using a US claims database, we conducted a retrospective cohort study of adults diagnosed with migraine between 2016 and 2018. We used a 12-month follow-up period to assess triptan and opioid utilization, stratified by the nine Census Bureau-designated divisions. To examine the geographic factors that affect triptan and opioid use among patients, we conducted two sets of multivariable analyses. First, we analyzed the odds of a patient being a triptan or opioid user in the follow-up period, defined as ≥1 triptan or opioid claim. We then analyzed the medication use rate among triptan or opioid users.
RESULTS
RESULTS
Overall, we had a final study population of 113,921 patients. In the follow-up period, 52.9% (60,247/113,921) [range: 48.0%-56.3%] of patients were triptan users and 41.0% (46,708/113,921) [range: 28.9%-48.4%] of patients were opioid users with significant differences across census divisions (p < 0.001). Triptan users had a mean (SD) of 4.8 (4.7) triptan claims annually with no significant differences across divisions (p = 0.188). Opioid users had a mean (SD) of 5.4 (6.8) opioid claims annually with significant differences across divisions (p < 0.001). The observed variation in opioid use stemmed from the proportion of patients using opioids in each region and not from the number of opioid prescriptions per user.
CONCLUSIONS
CONCLUSIONS
There was a significant geographic variation in the use of opioids and to a lesser degree the use of triptans. The widespread use of opioids and the large variation in use other than triptans as the standard of care suggest that improvements could be made in the acute treatment of migraine attacks.
Substances chimiques
Analgesics, Opioid
0
Tryptamines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1499-1510Subventions
Organisme : AbbVie
Informations de copyright
© 2021 American Headache Society.
Références
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20
Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499
American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1-18. doi:10.1111/head.13456
Lipton RB, Marcus SC, Shewale AR, Dodick DW, Viswanathan HN, Doshi JA. Acute treatment patterns in patients with migraine newly initiating a triptan. Cephalalgia. 2020;40(5):437-447. doi:10.1177/0333102420905307
Woolley JM, Bonafede MM, Maiese BA, Lenz RA. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399-1408. doi:10.1111/head.13157
Gower EW, Stein JD, Shekhawat NS, Mikkilineni S, Blachley TS, Pajewski NM. Geographic and demographic variation in use of ranibizumab versus bevacizumab for neovascular age-related macular degeneration in the United States. Am J Ophthalmol. 2017;184:157-166. doi:10.1016/j.ajo.2017.10.010
Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation therapy in stroke prevention in atrial fibrillation. Stroke. 2017;48(8):2289-2291. doi:10.1161/STROKEAHA.117.017683
Shafrin J, Ganguli A, Gonzalez YS, Shim JJ, Seabury SA. Geographic variation in the quality and cost of care for patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2016;22(12):1472-1481. doi:10.18553/jmcp.2016.22.12.1472
Schieber LZ, Guy GP, Seth P, et al. Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017. JAMA Netw Open. 2019;2(3):e190665. doi:10.1001/jamanetworkopen.2019.0665
Davis CS, Lieberman AJ, Hernandez-Delgado H, Suba C. Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: a national systematic legal review. Drug Alcohol Depend. 2019;194:166-172. doi:10.1016/j.drugalcdep.2018.09.022
García MC, Heilig CM, Lee SH, et al. Opioid prescribing rates in nonmetropolitan and metropolitan counties among primary care providers using an electronic health record system-United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2019;68(2):25-30. doi:10.15585/mmwr.mm6802a1
Area Health Resource Files. Health Resources & Services Administration. Accessed July 3, 2020. https://data.hrsa.gov/topics/health-workforce/ahrf
Nationwide Physician Specialties by State. IQVIA; 2019.
Basu S, Berkowitz SA, Phillips RL, Bitton A, Landon BE, Phillips RS. Association of primary care physician supply with population mortality in the United States, 2005-2015. JAMA Intern Med. 2019;179(4):506-514. doi:10.1001/jamainternmed.2018.7624
McDonald DC, Carlson K, Izrael D. Geographic variation in opioid prescribing in the U.S. J Pain. 2012;13(10):988-996. doi:10.1016/j.jpain.2012.07.007
MarketScan IBM. Research Databases for Life Sciences Researchers. IBM Watson Health; 2019.
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. doi:10.1097/01.mlr.0000182534.19832.83
van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626-633. doi:10.1097/MLR.0b013e31819432e5
Marcus SC, Shewale AR, Silberstein SD, et al. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020;40(7):639-649. doi:10.1177/0333102420915167
Katić BJ, Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to acute migraine medication: what does it mean, why does it matter? Headache. 2010;50(1):117-129. doi:10.1111/j.1526-4610.2009.01535.x
Fleming NH, Grade MM, Bendavid E. Impact of primary care provider density on detection and diagnosis of cutaneous melanoma. PLoS One. 2018;13(7):e0200097. doi:10.1371/journal.pone.0200097
Altschuler J, Margolius D, Bodenheimer T, Grumbach K. Estimating a reasonable patient panel size for primary care physicians with team-based task delegation. Ann Fam Med. 2012;10(5):396-400. doi:10.1370/afm.1400
Schuchat A, Houry D, Guy GP Jr. New data on opioid use and prescribing in the United States. JAMA. 2017;318(5):425-426. doi:10.1001/jama.2017.8913
Keyes KM, Cerdá M, Brady JE, Havens JR, Galea S. Understanding the rural-urban differences in nonmedical prescription opioid use and abuse in the United States. Am J Public Health. 2014;104(2):e52-e59. doi:10.2105/ajph.2013.301709
Davis CS, Piper BJ, Gertner AK, Rotter JS. Opioid prescribing laws are not associated with short-term declines in prescription opioid distribution. Pain Med. 2020;21(3):532-537. doi:10.1093/pm/pnz159
Lipton RB, Munjal S, Alam A, et al. Migraine in America Symptoms and Treatment (MAST) Study: baseline study methods, treatment patterns, and gender differences. Headache. 2018;58(9):1408-1426.
Li HU, Vincent M, Zhang X, et al. Acute migraine prescription patterns vary by baseline cardiovascular risk and clinical characteristics: a real-world evidence study. Pain Ther. 2020;9(2):499-509.
Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56(2):306-322. doi:10.1111/head.12755
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515-526. doi:10.2147/JPR.S13283